Complement receptor 2 in the regulation of the immune response

Clinical Immunology and Immunopathology

Volumn 88, Issue 2, 1998, Pages 123-132

  Tolnay, Mate ^b   Tsokos, George C ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NONE

Author keywords

B lymphocytes; Complement receptor 2; Immune response

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; B LYMPHOCYTE ACTIVATION; CELL STIMULATION; COMPLEMENT ACTIVATION; CROSS LINKING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MEMORY CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

EID: 0031688491     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1998.4552     Document Type: Review

References (108)

1. Fearon, D. T., and Carter, R. H., The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13, 127-149, 1995.
2. Janeway, C. A. J., and Medzhitov, R., Innate immunity: The virtues of a nonclonal system of recognition. Cell 91, 295-298, 1997.
3. Carroll, M. C., and Fischer, M. B., Complement and the immune response. Curr. Opin. Immunol. 9, 64-69, 1997.
4. Muller-Eberhard, H. J., Molecular organization and function of the complement system. Annu. Rev. Biochem. 57, 321-347, 1988.
5. Fingeroth, J. D., Weis, J. J., Tedder, T. F., Strominger, J. L., Biro, P. A., and Fearon, D. T., Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 81, 4510-4514, 1984.
6. Tanner, J., Weis, J., Fearon, D., Whang, Y., and Kieff, E., Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50, 203-213, 1987.
7. Delcayre, A. X., Salas, F., Mathur, S., Kovats, K., Lotz, M., and Lernhardt, W., Epstein-Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J. 10, 919-926, 1991.
8. Aubry, J. P., Pochon, S., Graber, P., Jansen, K. U., and Bonnefoy, J. Y., CD21 is a ligand for CD23 and regulates IgE production. Nature 358, 505-507, 1992.
9. Weis, J. J., Toothaker, L. E., Smith, J. A., Weis, J. H., and Fearon, D. T., Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J. Exp. Med. 167, 1047-1066, 1988.
10. Moore, M. D., Cooper, N. R., Tack, B. F., and Nemerow, G. R., Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc. Natl. Acad. Sci. USA 84, 9194-9198, 1987.
11. Nemerow, G. R., Moore, M. D., and Cooper, N. R., Structure and function of the B-lymphocyte Epstein-Barr virus/C3d receptor. Adv. Cancer Res. 54, 273-300, 1990.
12. Liu, Y.-J., Xu, J., de Bouteiller, O., Parham, C. L., Grouard, G., Djossou, O., de Saint-Vis, B., Lebeque, S., Banchereau, J., and Moore, K. W., Follicular dendritic cells specifically express the long CR2/CD21 isoform. J. Exp. Med. 185, 165-170, 1997.
13. Lowell, C. A., Klickstein, L. B., Carter, R. H., Mitchell, J. A., Fearon, D. T., and Ahearn, J. M., Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J. Exp. Med. 170, 1931-1946, 1989.
14. Weis, J. J., and Fearon, D. T., The identification of N-linked oligosaccharides on the human CR2/Epstein-Barr virus receptor and their function in receptor metabolism, plasma membrane expression, and ligand binding. J. Biol. Chem. 260, 13824-13830, 1985.
15. Aubry, J. P., Pochon, S., Gauchat, J. F., Nueda-Marin, A., Holers, V. M., Graber, P., Siegfried, C., and Bonnefoy, J. Y., CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J. Immunol. 152, 5806-5813, 1994.
16. Carter, R. H., Tuveson, D. A., Park, D. J., Rhee, S. G., and Fearon, D. T., The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J. Immunol. 147, 3663-3671, 1991.
17. Molina, H., Kinoshita, T., Inoue, K., Carel, J. C., and Holers, V. M., A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 145, 2974-2983, 1990.
18. Reynes, M., Aubert, J. P., Cohen, J. H., Audouin, J., Tricottet, V., Diebold, J., and Kazatchkine, M. D., Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J. Immunol. 135, 2687-2694, 1985.
19. Fischer, E., Delibrias, C., and Kazatchkine, M. D., Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 146, 865-869, 1991.
20. Tsoukas, C. D., and Lambris, J. D., Expression of EBV/C3d receptors on T cells: Biological significance. Immunol. Today 14, 56-59, 1993.
21. Tsoukas, C. D., and Lambris, J. D., Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur. J. Immunol. 18, 1299-1302, 1988.
22. Young, L. S., Sixbey, J. W., Clark, D., and Rickinson, A. B., Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet 1, 240-242, 1986.
23. Tedder, T. F., Clement, L. T., and Cooper, M. D., Expression of C3d receptors during human B cell differentiation: Immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133, 678-683, 1984.
24. Rasmussen, J. M., Marquart, H. V., Rask, R., Jepsen, H. H., and Svehag, S. E., Quantification of C3dg/Epstein-Barr virus receptors on human B cells and B cell lines. Complement 5, 98-107, 1988.
25. Stashenko, P., Nadler, L. M., Hardy, R., and Schlossman, S. F., Expression of cell surface markers after human B lymphocyte activation. Proc. Natl. Acad. Sci. USA 78, 3348-3852, 1981.
26. Inghirami, G., Nakamura, M., Balow, J. E., Notkins, A. L., and Casali, P., Model for studying virus attachment: Identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry. J. Virol. 62, 2453-2463, 1988.
27. Axcrona, K., Gray, D., and Leanderson, T., Regulation of B cell growth and differentiation via CD21 and CD40. Eur. J. Immunol. 26, 2203-2207, 1996.
28. Pillemer, S. R., Tsokos, G. C., Barbieri, S. A., Balow, J. E., and Golding, B., The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line. Cell. Immunol. 125, 386-395, 1990.
29. Cordier, M., Calender, A., Billaud, M., Zimber, U., Rousselet, G., Pavlish, O., Banchereau, J., Tursz, T., Bornkamm, G., and Lenoir, G. M., Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J. Virol. 64, 1002-1013, 1990.
30. Rayhel, E. J., Dehoff, M. H., and Holers, V. M., Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins. J. Immunol. 146, 2021-2026, 1991.
31. Yang, L. M., Behrens, M., and Weis, J. J., Identification of 5′-regions affecting the expression of the human CR2 gene. J. Immunol. 147, 2404-2410, 1991.
32. Hu, H., Martin, B. K., Weis, J. J., and Weis, J. H., Expression of the murine CD21 gene is regulated by promoter and intronic sequences. J. Immunol. 158, 4758-4768, 1997.
33. Makar, K. W., Pham, C. T., Dehoff, M. H., O'Connor, S. M., Jacobi, S. M., and Holers, V. M., An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J. Immunol. 160, 1268-1278, 1998.
34. Tolnay, M., Lambris, J. D., and Tsokos, G. C., Transcriptional regulation of the complement receptor 2 gene: Role of a heterogeneous nuclear ribonucleoprotein. J. Immunol. 159, 5492-5501, 1997.
35. Boyd, A. W., Anderson, K. C., Freedman, A. S., Fisher, D. C., Slaughenhoupt, B., Schlossman, S. F., and Nadler, L. M., Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J. Immunol. 134, 1516-1523, 1985.
36. Griffioen, A. W., Toebes, E. A., Zegers, B. J., and Rijkers, G. T., Role of CR2 in the human adult and neonatal in vitro antibody response to type 4 pneumococcal polysaccharide. Cell. Immunol. 143, 11-22, 1992.
37. Timens, W., Boes, A., and Poppema, S., Human marginal zone B cells are not an activated B cell subset: strong expression of CD21 as a putative mediator for rapid B cell activation. Eur. J. Immunol. 19, 2163-2166, 1989.
38. Molina, H., Holers, V. M., Li, B., Fung, Y., Mariathasan, S., Goellner, J., Strauss-Schoenberger, J., Karr, R. W., and Chaplin, D. D., Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93, 3357-3361, 1996.
39. Takahashi, K., Kozono, Y., Waldschmidt, T. J., Berthiaume, D., Quigg, R. J., Baron, A., and Holers, V. M., Mouse complement receptor type 1 (CR1; CD35) and type 2 (CR2; CD21) expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/1pr mice. J. Immunol. 159, 1557-1569, 1997.
40. Tsokos, G. C., Thyphronitis, G., Jack, R. M., and Finkelman, F. D., Ligand-loaded but not free complement receptors for C3b/C4b and C3d co-cap with cross-linked B cell surface IgM and IgD. J. Immunol. 141, 1261-1266, 1988.
41. Changelian, P. S., and Fearon, D. T., Tissue-specific phosphorylation of complement receptors CR1 and CR2. J. Exp. Med. 163, 101-105, 1986.
42. Barel, M., Vazquez, A., Charriaut, C., Aufredou, M. T., Galanaud, P., and Frade, R., gp 140, the C3d/EBV receptor (CR2), is phosphorylated upon in vitro activation of human peripheral B lymphocytes. FEBS Lett. 197, 353-356, 1986.
43. Matsumoto, A. K., Kopicky-Burd, J., Carter, R. H., Tuveson, D. A., Tedder, T. F., and Fearon, D. T., Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173, 55-64, 1991.
44. Bradbury, L. E., Kansas, G. S., Levy, S., Evans, R. L., and Tedder, T. F., The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149, 2841-2850, 1992.
45. Tedder, T. F., Zhou, L. J., and Engel, P., The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 1994.
46. Oren, R., Takahashi, S., Doss, C., Levy, R., and Levy, S., TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol. Cell. Biol. 10, 4007-4015, 1990.
47. Matsumoto, A. K., Martin, D. R., Carter, R. H., Klickstein, L. B., Ahearn, J. M., and Fearon, D. T., Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J. Exp. Med. 178, 1407-1417, 1993.
48. Tuveson, D. A., Ahearn, J. M., Matsumoto, A. K., and Fearon, D. T., Molecular interactions of complement receptors on B lymphocytes: A CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 173, 1083-1089, 1991.
49. O'Rourke, L., Tooze, R., and Fearon, D. T., Co-receptors of B lymphocytes. Curr. Opin. Immunol. 9, 324-329, 1997.
50. Tuveson, D. A., Carter, R. H., Soltoff, S. P., and Fearon, D. T., CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260, 986-989, 1993.
51. Carter, R. H., and Fearon, D. T., CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-107, 1992.
52. Rickert, R. C., Rajewsky, K., and Roes, J., Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376, 352-355, 1995.
53. Ahearn, J. M., Fischer, M. B., Croix, D., Goerg, S., Ma, M., Xia, J., Zhou, X., Howard, R. G., Rothstein, T. L., and Carroll, M. C., Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity. 4, 251-262, 1996.
54. Reljic, R., Cosentino, G., and Gould, H. J., Function of CD23 in the response of human B cells to antigen. Eur. J. Immunol. 27, 572-575, 1997.
55. Tsokos, G. C., Lambris, J. D., Finkelman, F. D., Anastassiou, E. D., and June, C. H., Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J. Immunol. 144, 1640-1645, 1990.
56. Luxembourg, A. T., and Cooper, N. R., Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J. Immunol. 153, 4448-4457, 1994.
57. Sugano, N., Chen, W., Roberts, M. L., and Cooper, N. R., Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-κB induction. J. Exp. Med. 186, 731-737, 1997.
58. Beg, A. A., and Baltimore, D., An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science 274, 782-783, 1996.
59. Wang, C. Y., Mayo, M. W., and Baldwin, A. S. J., TNF and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274, 784-787, 1996.
60. Antwerp, D. J. V., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M., Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274, 787-789, 1996.
61. Bonnefoy, J. Y., Henchoz, S., Hardie, D., Holder, M. J., and Gordon, J., A subset of anti-CD21 antibodies promote the rescue of germinal center B cells from apoptosis. Eur. J. Immunol. 23, 969-972, 1993.
62. Kozono, Y., Duke, R. C., Schleicher, M. S., and Holers, V. M., Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from antisurface IgM-induced apoptosis. Eur. J. Immunol. 25, 1013-1017, 1995.
63. Bouillie, S., Barel, M., Drane, P., Cassinat, B., Balbo, M., Holers, V. M., and Frade, R., Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pplOS phosphorylation through two distinct pathways. Eur. J. Immunol. 25, 2661-2667, 1995.
64. Balbo, M., Barel, M., Bouillie, S., Drane, P., Cassinat, B., and Frade, R., Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2. Mol. Immunol. 32, 1295-1298, 1995.
65. Barel, M., Gauffre, A., Lyamani, F., Fiandino, A., Hermann, J., and Frade, R., Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes. J. Immunol. 147, 1286-1291, 1991.
66. Frade, R., Gauffre, A., Hermann, J., and Barel, M., EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein. J. Immunol. 149, 3232-3238, 1992.
67. Barel, M., Balbo, M., Gauffre, A., and Frade, R., Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein. Mol. Immunol. 32, 389-397, 1995.
68. Jackson, C. G., Ochs, H. D., and Wedgewood, R. J., Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N. Engl. J. Med. 300, 1124-1129, 1979.
69. Bottger, E. C., Hoffmann, T., Hadding, U., and Bitter-Sauermann, D., Influence of genetically inherited complement deficiencies on humoral immune response in guinea pigs. J. Immunol. 135, 4100-4107, 1985.
70. Klaus, G. G., and Humphrey, J. H., The generation of memory B cells. I. The role of C3 in the generation of B memory cells. Immunology 33, 31-40, 1977.
71. Schifferli, J. A., Ng, Y. C., and Peters, D. K., The role of complement and its receptor in the elimination of immune complexes. N. Engl. J. Med. 315, 488-495, 1986.
72. Kazatchkine, M. D., and Fearon, D. T., Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodefic. Rev. 2, 17-41, 1990.
73. Atkinson, J. P., Complement deficiency. Predisposing factor to autoimmune syndromes. Am. J. Med. 85, 45-47, 1988.
74. Pepys, M. B., Role of complement in induction of antibody production in vivo. Effect of cobra factor and and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J. Exp. Med. 140, 126-145, 1974.
75. Clark, E. A., and Lane, P. L., Regulation of human B-cell activation and adhesion. Annu. Rev. Immunol. 9, 97-127, 1991.
76. Martinelli, G. P., Matsuda, T., and Osler, A. G., Studies of immunosuppression by cobra venom factor. I. On early IgG and IgM responses to sheep erythrocytes and DNP-protein conjugates. J. Immunol. 121, 2043-2047, 1978.
77. Matsuda, T., Martinelli, G. P., and Osler, A. G., Studies on immunosuppression by cobra venom factor. II. On responses to DNP-Ficoll and DNP-polyacrylamide. J. Immunol. 121, 2048-2051, 1978.
78. Fischer, M. B., Ma, M., Goerg, S., Zhou, X., Xia, J., Finco, O., Han, S., Kelsoe, G., Howard, R. G., Rothstein, T. L., Kremmer, E., Rosen, F. S., and Carroll, M. C., Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 157, 549-556, 1996.
79. Heyman, B., Wiersma, E. J., and Kinoshita, T., In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J. Exp. Med. 172, 665-668, 1990.
80. Thyphronitis, G., Kinoshita, T., Inoue, K., Schweinle, J. E., Tsokos, G. C., Metcalf, E. S., Finkelman, F. D., and Balow, J. E., Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J. Immunol. 147, 224-230, 1991.
81. Wiersma, E. J., Kinoshita, T., and Heyman, B., Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors. Eur. J. Immunol. 21, 2501-2506, 1991.
82. Gustavsson, S., Kinoshita, T., and Heyman, B., Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. J. Immunol. 154, 6524-6528, 1995.
83. Hebell, T., Ahearn, J. M., and Fearon, D. T., Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254, 102-105, 1991.
84. Croix, D. A., Ahearn, J. M., Rosengard, A. M., Han, S., Kelsoe, G., Ma, M., and Carroll, M. C., Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183, 1857-1864, 1996.
85. Carter, R. H., and Fearon, D. T., Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. J. Immunol. 143, 1755-1760, 1989.
86. Nemerow, G. R., McNaughton, M. E., and Cooper, N. R., Binding of monoclonal antibody to the Epstein-Barr virus (EBV)/ CR2 receptor induces activation and differentiation of human B lymphocytes. J. Immunol. 135, 3068-3073, 1985.
87. Hatzfeld, A., Fischer, E., Levesque, J. P., Perrin, R., Hatzfeld, J., and Kazatchkine, M. D., Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line. J. Immunol. 140, 170-175, 1988.
88. Melchers, F., Erdei, A., Schulz, T., and Dierich, M. P., Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 317, 264-267, 1985.
89. Mongini, P. K. A., Vilensky, M. A., Highet, P. F., and Inman, J., The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 159, 3782-3791, 1997.
90. Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C., and Fearon, D. T., C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 271, 348-350, 1996.
91. Erdei, A., Melchers, F., Schulz, T., and Dierich, M., The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. Eur. J. Immunol. 15, 184-188, 1985.
92. Bohnsack, J. F., and Cooper, N. R., CR2 ligands modulate human B cell activation. J. Immunol. 141, 2569-2576, 1988.
93. Burton, G. F., Conrad, D. H., Szakal, A. K., and Tew, J. G., Follicular dendritic cells (FDC) and B cell costimulation. J. Immunol. 150, 31-38, 1993.
94. Tew, J. G., Wu, J., Qin, D., Helm, S., Burton, G. F., and Szakal, A. K., Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Immunol. Rev. 156, 39-52, 1997.
95. Hunter, R. L., and Bennett, B., The adjuvant activity of non- ionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133, 3167-3175, 1984.
96. Szebeni, J., Muggia, F. M., and Alving, C. R., Complement activation by Cremophor EL as a possible contributor to hypersensitivity to Paclitaxel: An In Vitro study. J. Natl. Cancer Inst. 90, 300-306, 1998.
97. Frade, R., Barel, M., Ehlin-Henriksson, B., and Klein, G., gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. USA 82, 1490-1493, 1985.
98. Kearns-Jonker, M., Monell-Torrens, E., Abbasi, F., Holers, V. M., Notkins, A. L., and Sigounas, G., EBV binds to lymphocytes of transgenic mice that express the human CR2 gene. Virus Res. 50, 85-94, 1997.
99. Gras, G., Richard, Y., Roques, P., Olivier, R., and Dormont, D., Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type I. Blood 81, 1808-1818, 1993.
100. Speth, C., Kacani, L., and Dierich, M. P., Complement receptors in HIV infection. Immunol. Rev. 159, 49-67, 1997.
101. Wickham, T. J., Shuler, M. L., and Hammer, D. A., A simple model to predict the effectiveness of molecules that block attachment of human rhinoviruses and other viruses. Biotechnol. Prog. 11, 164-170, 1995.
102. Aguado, M. T., Lambris, J. D., Tsokos, G. C., Burger, R., Bitter-Suermann, D., Tamerius, J. D., Dixon, F. J., and Theofilopoulos, A. N., Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J. Clin. Invest. 76, 1418-1426, 1985.
103. Wilson, J. G., Ratnoff, W. D., Schur, P. H., and Fearon, D. T., Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 29, 739-747, 1986.
104. Marquart, H. V., Svendsen, A., Rasmussen, J. M., Nielsen, C. H., Junker, P., Svehag, S. E., and Leslie, R. G., Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 101, 60-65, 1995.
105. Scott, M. E., Landay, A. L., Lint, T. F., and Spear, G. T., In vivo decrease in the expression of complement receptor 2 (CR2) on B cells in HIV infection. AIDS 7, 37-41, 1993.
106. Munson, L. G., Scott, M. E., Landay, A. L., and Spear, G. T., Decreased levels of complement receptor 1 (CD35) on B lymphocytes in persons with HIV infection. Clin. Immunol. Immunopathol. 75, 20-25, 1995.
107. Prodeus, A., Goerg, S., Xia, J., Ma, M., and Carroll, M. C., Role of complement C4 in regulation of autoreactive B cells in 1pr/1pr mice. Arthritis Rheum. 40, S122 1997.
108. Birmingham, D. J., Erythrocyte complement receptors. Crit. Rev. Immunol. 15, 133-154, 1995.